Weekly Roundup: July 5-9

ICYMI, some of this week’s featured content includes AI in dermatology, mental health and PsA treatment, AD therapies, at-home keratosis pilaris treatments, plus more.

POLL: Do you educate your patients about photoprotection?

The Mainstream Patient: July 5, 2021

This week’s edition of The Mainstream Patient features stories about perioral dermatitis, rosacea, forever chemicals in cosmetics, plus more.

July FDA Approvals to Watch

Explore what dermatologic drugs the FDA will decide to approve during July 2021.

Arcutis Biotherapeutics to Terminate Phase 2a Vitiligo Study

Arcutis Biotherapeutics announced early termination of its phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo citing to inadequate local drug delivery to the skin.

Mental Health Affects Psoriatic Arthritis Treatment

Patients with anxiety/depression and psoriatic arthritis (PsA) are much less likely to achieve long-term remission. Mental health comorbidities need to be a more important part of PsA treatment.

ASDS Annual Meeting Goes Hybrid

The American Society for Dermatologic Surgery is having two meeting experiences this year, an in-person meeting October 14-17 in Chicago, Illinois and a virtual meeting November 19-21.

How to Choose Integrative AD Therapies

From oat oil to acupuncture to prebiotics, there are many topical, oral, and manual options.

OncoSec, Merck Enter Agreement for Late-Stage Metastatic Melanoma Combo

OncoSec Medical Inc. and Merck have entered into a supply and clinical trial agreement for pembrolizumab (Keytruda) and tavokinogene telseplasmid (Tavo) for the potential treatment of late-stage metastatic melanoma.

FDA Approves Pembrolizumab for Locally Advanced cSCC

The FDA has expanded the label for pembrolizumab for use as a monotherapy in the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

At-Home Treatment Recommendations for Keratosis Pilaris

The AAD has provided various at-home treatments for keratosis pilaris that physicians can recommend to their patients.

Brickell BioTech Provides Update on Phase 3 Sofpironium Bromide Gel Studies

Brickell BioTech, Inc announced the completion of its Cardigan I study and final enrollment of the Cardigan II study.

The Cutaneous Connection: Episode 26- AI in Dermatology and Racial Diagnostic Bias

The introduction of artificial intelligence into dermatology has been met with mixed emotions from the medical community. In this episode, Ade Adamson, MD, MPP, explains the benefits and detriments of the application, accuracy, and potential racial diagnostic bias.

Journey Medical, Dr. Reddy’s to Commercialize and Develop DFD-29 for Rosacea

Journey Medical Corporation and Dr. Reddy’s Laboratories Ltd. have joined forces for the development and commercialization of DFD-19 as a treatment for rosacea.